Predicting future brain atrophy based on longitudinal MRI

Neuron loss is a key feature of neurodegenerative diseases often leading to brain atrophy detectable through magnetic resonance imaging (MRI). Various brain atrophy measures are essential in research of Alzheimer' disease (AD) and related dementias. This study aims to forecast future annual percentage changes in hippocampal, ventricular, and total gray matter (TGM) volumes in individuals with varying cognitive statuses, from healthy to dementia. We developed a machine learning model using elastic net linear regression and tested two approaches: (1) a baseline model using predictors from a single-time-point and (2) a longitudinal model using predictors derived from longitudinal MRI. Both approaches were evaluated with MRI-only models and models that combined MRI with additional risk factors (age, sex, APOE4, and baseline diagnosis). Cross-validated Pearson correlation scores between predicted and actual annual percentage changes were 0.62 for the hippocampus, 0.51 for the ventricles, and 0.41 for TGM, using the longitudinal MRI + risk factor model. Longitudinal models consistently outperformed baseline models, and models including risk factors outperformed the MRI only model. Validation using an external dataset confirmed these findings, highlighting the value of predictors derived based on longitudinal data. We further studied the value of the predicted atrophy/enlargement rates for clinical status progression prediction across three different datasets. Predicted atrophy was a consistently better indicator of progression to mild cognitive impairment and dementia than present-day regional volumes, with the longitudinal atrophy prediction model typically outperforming the baseline model in terms of clinical status prediction. Future atrophy prediction has significant potential for assessing the risk of cognitive decline, even in cognitively unimpaired individuals, and can aid in selecting participants for clinical trials of disease-modifying drugs for AD.

Authors

Institutions

Publication Details

Journal
Journal of Alzheimer s Disease
Published
2026-07-28
DOI
https://doi.org/10.1177/13872877261471049
Primary Topic
Brain Tumor Detection and Classification
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Predicting future brain atrophy based on longitudinal MRI

Jussi Tohka, Maryam Hadji, Elaheh Moradi
Journal of Alzheimer s Disease
Brain Tumor Detection and Classification
article

Predicting future brain atrophy based on longitudinal MRI

Jussi Tohka, Maryam Hadji, Elaheh Moradi
article en

Abstract

Neuron loss is a key feature of neurodegenerative diseases often leading to brain atrophy detectable through magnetic resonance imaging (MRI). Various brain atrophy measures are essential in research of Alzheimer' disease (AD) and related dementias. This study aims to forecast future annual percentage changes in hippocampal, ventricular, and total gray matter (TGM) volumes in individuals with varying cognitive statuses, from healthy to dementia. We developed a machine learning model using elastic net linear regression and tested two approaches: (1) a baseline model using predictors from a single-time-point and (2) a longitudinal model using predictors derived from longitudinal MRI. Both approaches were evaluated with MRI-only models and models that combined MRI with additional risk factors (age, sex, APOE4, and baseline diagnosis). Cross-validated Pearson correlation scores between predicted and actual annual percentage changes were 0.62 for the hippocampus, 0.51 for the ventricles, and 0.41 for TGM, using the longitudinal MRI + risk factor model. Longitudinal models consistently outperformed baseline models, and models including risk factors outperformed the MRI only model. Validation using an external dataset confirmed these findings, highlighting the value of predictors derived based on longitudinal data. We further studied the value of the predicted atrophy/enlargement rates for clinical status progression prediction across three different datasets. Predicted atrophy was a consistently better indicator of progression to mild cognitive impairment and dementia than present-day regional volumes, with the longitudinal atrophy prediction model typically outperforming the baseline model in terms of clinical status prediction. Future atrophy prediction has significant potential for assessing the risk of cognitive decline, even in cognitively unimpaired individuals, and can aid in selecting participants for clinical trials of disease-modifying drugs for AD.

Journal of Alzheimer s Disease
University of Eastern Finland (FI)
U.S. Department of Defense, Alzheimer's Association, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Biogen, University of Southern California, Meso Scale Diagnostics, Alzheimer's Disease Neuroimaging Initiative, BioClinica, Novartis Pharmaceuticals Corporation, Northern California Institute for Research and Education, Commonwealth Scientific and Industrial Research Organisation, Academy of Finland, Eisai, Servier, H. Lundbeck A/S, IXICO, National Institutes of Health, Genentech, Canadian Institutes of Health Research
Openalex Percentile: Top 100%
Brain Tumor Detection and Classification
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.